<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132935">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072278</url>
  </required_header>
  <id_info>
    <org_study_id>15835A</org_study_id>
    <secondary_id>2013-004015-53</secondary_id>
    <nct_id>NCT02072278</nct_id>
  </id_info>
  <brief_title>Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore a neurophysiological marker (electroencephalography) of cognitive effect of
      vortioxetine
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Battery of EEG measurements</measure>
    <time_frame>The EEG task battery will be conducted on Days -1 and starting 6 hours post-dose on Days 1 and 3 of each treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak amplitude and latency of P300
AUC of qEEG power spectral bands delta, theta, alpha, beta and gamma
AUC of evoked gamma power spectral band
Peak amplitude and latency of N200
Peak amplitude and latency of error related negativity
Peak amplitudes and latencies in the evoked responses during successful versus non-successful encoding in the verbal memory task between treatments</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Men</condition>
  <arm_group>
    <arm_group_label>Vortioxetine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>encapsulated tablets; 3 daily doses in each treatment period; orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>encapsulated tablets; 3 daily doses in each treatment period; orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram 15 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>encapsulated tablets; 3 daily doses in each treatment period; orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsules; 3 daily doses in each treatment period; orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine 10 mg</intervention_name>
    <arm_group_label>Vortioxetine 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine 20 mg</intervention_name>
    <arm_group_label>Vortioxetine 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram 15 mg</intervention_name>
    <arm_group_label>Escitalopram 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a normal resting EEG at screening visit

          -  The subject is able to perform tasks with an auditory stimulus

          -  The subject is not visually impaired - normal prescription glasses are accepted

          -  The subject has a normal circadian rhythm, defined as a person who usually wakes
             between 6:00 and 9:00 a.m. and goes to sleep between 9:00 pm and midnight.

        Exclusion Criteria:

          -  The subject has worked shifts, including night duty, or has travelled across &gt;3 time
             zones &lt;2 weeks prior to the first dose of IMP.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>FR801</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
